A 3 Month, Randomized, Open Label, Multi-center Study of Technosphere/Insulin Compared to Insulin...
Diabetes MellitusType 1A 3 month, randomized, open label, multi-center study of Technosphere/Insulin compared to insulin aspart in subjects with type 1 diabetes mellitus receiving insulin glargine
A Study for Patients With Diabetes Mellitus (IOPA)
Diabetes MellitusType 12 moreThe purpose of this study is to compare glycemic control (HbA1c) in Chinese patients with type 1 or type 2 diabetes when treated with insulin lispro low mixture and human insulin 30/70.
Obtain a Good Blood Glucose Control With the Paradigm Real Time System
Type 1 DiabetesIn this study, subjects with insufficient metabolic control despite optimized basal-bolus injection regimens were randomily assigned to either the Mini- Med Paradigm REAL-Time insulin pump (PRT), an insulin pump that can receive and display CGM data from a separate subcutaneous glucose sensor, or conventional CSII, and compared glycemic outcomes after 6 months.
Investigating the Postprandial Glucose Metabolism After Treatment With Faster-acting Insulin Aspart...
DiabetesDiabetes Mellitus1 moreThis trial is conducted in Europe. The aim of the trial is to investigate the postprandial glucose metabolism after treatment with faster-acting insulin aspart in subjects with type 1 diabetes.
Comparison of Explorative Formulation of Insulin Degludec and Insulin Aspart Co-formulation Versus...
DiabetesDiabetes Mellitus3 moreThis trial is conducted in Europe. The aim of this trial is to compare different ratios of explorative formulations, not similar to the proposed commercial formulation, of IDegAsp (co-formulation of insulin degludec/insulin aspart and insulin aspart) with separately injected, simultaneous doses of insulin degludec (insulin 454), and insulin aspart, compared with biphasic insulin aspart 30 in male subjects with type 1 and type 2 diabetes mellitus. Trial part 1 is a five-period cross-over trial with incomplete block-design in subjects with type 1 diabetes where each subject will be randomised to five out of the ten possible treatments. Each treatment consists of an injection of the insulin product followed by a euglycemic clamp with a washout period of 7-15 days between treatments. Trial part 2 is a three-period cross-over trial with complete blockdesign in subjects with type 2 diabetes. Each treatment consists of an injection of the insulin product followed by a euglycaemic clamp with a washout period of 7-15 days between treatments.
Incidence of Macular Edema After Panretinal Photocoagulation (PRPC) Performed in a Single Session...
Diabetes Type 1 or 2 With Diabetic RetinopathyThe aim of this study is to show that PRPC performed in a single session using a Pascal laser leads to better management of the disease (better rate of regression of neovessels, lower risk of a loss of visual acuity in the long term related to macular edema), a saving of time and better comfort for both patient and doctor.
Applying the "New Authority" Model in the Treatment of Poorly Controlled Diabetic Adolescents and...
Type 1 DiabetesIt is presumed that families of poorly controlled diabetic adolescents (type 1) would benefit from parents' counselling, guided by "the New Authority" model.
The Performance of an Artificial Pancreas at Home in People With Type 1 Diabetes
Type 1 DiabetesThe overall aim of the study is to evaluate the performance of Artificial Pancreas or Closed Loop Glucose-Sensing Insulin-Delivery system in comparison to current best available technology represented by Sensor Augmented Pump Therapy (SAPT) in patients with Type 1 Diabetes.
Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With...
Type 1 Diabetes MellitusThis Phase 3 study was intended to demonstrate superiority of either sotagliflozin high dose or low dose versus placebo on glycosylated hemoglobin A1C (A1C) reduction at Week 24 when used as an adjunct in adult participants with type 1 diabetes mellitus (T1D) who have inadequate glycemic control with insulin therapy.
A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients...
Type 1 Diabetes MellitusPrimary Objective: To demonstrate that morning injection of Toujeo (HOE901-U300) compared to Lantus provides better glycemic control evaluated by Continuous Glucose Monitoring (CGM) in adult participants with type 1 diabetes mellitus. Secondary Objective: To demonstrate that treatment with HOE901-U300 compared to Lantus provides: Lower incidence rate of nocturnal symptomatic hypoglycemia; Better glucose control coverage during the last hours of CGM before next basal-insulin dosing; Less variability in CGM profile.